Low-dose radiation treatment for painful plantar enthesophyte: a highly effective therapy with little side effects.


Journal

European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857

Informations de publication

Date de publication:
23 Feb 2022
Historique:
received: 20 08 2021
accepted: 13 01 2022
entrez: 24 2 2022
pubmed: 25 2 2022
medline: 22 3 2022
Statut: epublish

Résumé

Plantar enthesophyte is a common degenerative disorder. Surgical and medical treatment options are associated with either poor outcome or high percentage of relapse. Observations have indicated a beneficial effect of radiation therapy. We therefore wanted to evaluate pain reduction using orthovolt or cobalt-based radiation treatment for painful plantar enthesophyte and determine long-term response as well as prognostic parameters in this condition. We identified a total of 102 consecutive patients treated for a total of 117 symptomatic heel spurs. 59 patients were treated with cobalt radiation, 31 patients with orthovolt therapy and 12 patients with both radiation systems. Primary outcome measure was pain reduction being scored using the modified Rowe Score prior therapy, at the end of each treatment series as well as after 6 weeks. Secondary outcome measure was long-term outcome, evaluated in patients with a follow-up period of longer than 3 years. Before radiation therapy, 61 patients (60.4%) had a score of 0, significant strong pain. At the time of completion of radiation treatment, 3 patients (2.7%) were pain-free (score of 30), whereas 8 patients (7.9%) had still severe pain (score 0). 6 weeks after radiation therapy, 33 patients (32.7%) were pain-free and 8 patients (7.9%) had severe pain (score 0), while at the time data of collection, 74 patients (73%) were free of pain and 1 patient (1%) had strong pain (score 0). Duration of pain before the start of radiation treatment was a significant prognostic factor (p = 0.012) for response to treatment. Radiotherapy of painful plantar enthesophyte is a highly effective therapy with little side effects providing long-term therapeutic response. The only significant prognostic parameter for response to treatment is the duration of pre-radiation therapy pain. Early integration of radiation therapy in the treatment seems to result in superior pain reduction.

Identifiants

pubmed: 35197107
doi: 10.1186/s40001-022-00642-x
pii: 10.1186/s40001-022-00642-x
pmc: PMC8867737
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

28

Informations de copyright

© 2022. The Author(s).

Références

Z Orthop Ihre Grenzgeb. 1998 Mar-Apr;136(2):169-74
pubmed: 9615981
J Clin Virol. 2010 Feb;47(2):189-92
pubmed: 20034850
J Orthop Sports Phys Ther. 1999 Dec;29(12):756-60
pubmed: 10612073
Am Fam Physician. 1999 Dec;60(9):2504
pubmed: 10605984
Strahlenther Onkol. 2020 Dec;196(12):1116-1127
pubmed: 32651595
Am J Sports Med. 1997 May-Jun;25(3):312-6
pubmed: 9167809
Cleve Clin J Med. 1999 Apr;66(4):231-5
pubmed: 10199059
Strahlenther Onkol. 1999 Nov;175(11):541-7
pubmed: 10584123
Acta Chir Orthop Traumatol Cech. 2019;86(3):212-215
pubmed: 31333186
Strahlentherapie. 1955 Jul;97(3):349-61
pubmed: 13267631
Zhongguo Gu Shang. 2018 Jun 25;31(6):504-509
pubmed: 29945403
Foot Ankle Int. 2002 Apr;23(4):301-8
pubmed: 11991474
J Bone Joint Surg Am. 1975 Jul;57(5):672-3
pubmed: 1150711
J Foot Ankle Surg. 2002 May-Jun;41(3):166-72
pubmed: 12075904
Acta Oncol. 2007;46(2):239-46
pubmed: 17453376
J Back Musculoskelet Rehabil. 2021;34(2):279-287
pubmed: 33285624
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):828-43
pubmed: 14967440
Strahlenther Onkol. 2007 Jan;183(1):3-9
pubmed: 17225939
Strahlenther Onkol. 2006 Dec;182(12):733-9
pubmed: 17149581
Strahlenther Onkol. 2015 Sep;191(9):742-9
pubmed: 26051282
Strahlenther Onkol. 2004 Aug;180(8):502-9
pubmed: 15292971
Clin Podiatr Med Surg. 1991 Jan;8(1):153-66
pubmed: 2015526
J Bone Joint Surg Br. 1994 Jan;76(1):140-2
pubmed: 8300659
Z Rheumaforsch. 1967 Oct 13;26(9):353-63
pubmed: 5598308
Br Med J. 1978 Jul 8;2(6130):90-1
pubmed: 667574
Foot Ankle Int. 2002 Apr;23(4):309-13
pubmed: 11991475
Radiobiol Radiother (Berl). 1967;8(4):419-22
pubmed: 5603947
Strahlenther Onkol. 2003 Nov;179(11):774-8
pubmed: 14605748
Clin Orthop Relat Res. 1994 Sep;(306):192-6
pubmed: 8070194
Unfallchirurg. 1998 Dec;101(12):914-8
pubmed: 10025241
Ann Oncol. 2020 Aug;31(8):1087-1088
pubmed: 32360743
Aust Fam Physician. 1996 Jun;25(6):875-81; 884-5
pubmed: 8687311
J Am Podiatr Med Assoc. 1993 Jan;83(1):39-42
pubmed: 8419629
Orthopedics. 1993 Oct;16(10):1153-63
pubmed: 8255812
Rofo. 1995 Jun;162(6):502-5
pubmed: 7605963
Radiology. 1996 Jul;200(1):271-6
pubmed: 8657925
J Am Acad Orthop Surg. 1997 Mar;5(2):109-117
pubmed: 10797213
Strahlentherapie. 1965 May;127:44-8
pubmed: 14310664
Eur J Orthop Surg Traumatol. 2018 May;28(4):757
pubmed: 29260310
J Chin Med Assoc. 2020 Jun;83(6):537-543
pubmed: 32349035
Radiobiol Radiother (Berl). 1972;13(2):181-6
pubmed: 4636554
J Med Assoc Thai. 1992 Jun;75(6):337-40
pubmed: 1487681
Z Orthop Ihre Grenzgeb. 1998 Sep-Oct;136(5):402-6
pubmed: 9823634
Strahlenther Onkol. 1996 Jul;172(7):376-83
pubmed: 8693404
J Am Podiatr Med Assoc. 2019 Mar;109(2):172-173
pubmed: 30648880
Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e455-62
pubmed: 22836057
Strahlenther Onkol. 1995 Sep;171(9):534-8
pubmed: 7570302
Eur J Orthop Surg Traumatol. 2017 May;27(4):569
pubmed: 28265759
Radiobiol Radiother (Berl). 1980;21(3):233-6
pubmed: 7455006
Strahlenther Onkol. 1995 Apr;171(4):202-6
pubmed: 7740407
Sports Med. 1993 May;15(5):344-52
pubmed: 8100639
J Biol Regul Homeost Agents. 2019 Nov-Dec;33(6):1949-1954
pubmed: 31939270
Ophthalmology. 2015 Mar;122(3):524-30
pubmed: 25439613
Strahlenther Onkol. 2017 Jun;193(6):483-490
pubmed: 28243722
Dtsch Med Wochenschr. 1993 Apr 8;118(14):493-8
pubmed: 8467752

Auteurs

Freddy Djiepmo (F)

Department of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany.

Bálint Tamaskovics (B)

Department of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany.

Edwin Bölke (E)

Department of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany. boelke@med.uni-duesseldorf.de.
Klinik Für Strahlentherapie Und Radiologische Onkologie, Heinrich-Heine-Universität, Moorenstr. 5, 40225, Düsseldorf, Germany. boelke@med.uni-duesseldorf.de.

Matthias Peiper (M)

Medical Faculty, Heinrich-Heine-University, Dusseldorf, Germany.

Jan Haussmann (J)

Department of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany.

Judith Neuwahl (J)

Department of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany.

Danny Jazmati (D)

Department of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany.

Kitti Maas (K)

Department of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany.

Livia Schmidt (L)

Department of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany.

Roman Gelzhäuser (R)

Institute of Mathematical Statistics and Probability Theory, Heinrich-Heine-University, Dusseldorf, Germany.

Christoph Schleich (C)

Radiology Dusseldorf/Viersen, Ernst-Schneider-Platz 1, Dusseldorf, Germany.

Stefanie Corradini (S)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Klaus Orth (K)

University of Hannover, Hannover, Germany.

Martijn van Griensven (M)

Department cBITE, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, The Netherlands.

Amir Rezazadeh (A)

Department of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany.

Kimia Karimi (K)

Department of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany.

Wilfried Budach (W)

Department of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany.

Christiane Matuschek (C)

Department of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH